apple
- 25 Mar 2004 20:47
cynic
- 05 Mar 2008 14:52
- 1124 of 1451
i thought you were joking ...... i wouldn't touch SEO with yours, never mind mine! ..... i see no real reason for the rise other than lemmings following sheep
cynic
- 05 Mar 2008 15:49
- 1126 of 1451
go to SEO
micky468
- 05 Mar 2008 16:21
- 1127 of 1451
cynic i'm in seo and oxb they will make money this time round you no i like an under dog makes me fill good when they come up and you can make good money on them they need time their like a baby thats start to walk soon their run then you can;t catch them.........;-))
micky468
- 05 Mar 2008 16:32
- 1129 of 1451
driver
you have to have fath in what you put your money in but it hard when you go short me i'm happy to hold and avg down when i fill it right to do that ..most of my shares i've held for say 2/3 years but thats fine ......;-))
cynic
- 05 Mar 2008 16:39
- 1131 of 1451
SEO lives on SEO thread!
micky468
- 05 Mar 2008 16:42
- 1132 of 1451
no i talking about oxb cynic...............;-((
cynic
- 05 Mar 2008 16:50
- 1134 of 1451
cheeky boy - lol
Toya
- 06 Mar 2008 07:07
- 1135 of 1451
Don't forget guys: OXB full-year prelims are out next Monday 10th March - which may or may not be relevant to your discussion here :)
"Simultaneously to the analyst briefing at 10.30 am, there will be a live audio web cast of the results presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (10.20 am) before the start of the briefing. This will also be available for replay shortly after the presentation."
Toya
- 06 Mar 2008 07:21
- 1136 of 1451
Just seen this snippet from today's Independent:
"Oxford Biomedica's shares climbed by 3.25p, or almost 13 per cent, to 28.5p after late rumours suggested that the company, which is due to publish its full-year results on Monday, was set to issue a positive update on ProSavin, its gene-based therapy for Parkinson's disease."
robstuff
- 06 Mar 2008 19:40
- 1137 of 1451
yeah cynic, takes me a while to get round to reading it
robstuff
- 07 Mar 2008 14:51
- 1138 of 1451
could be exciting news on Monday!!
robstuff
- 10 Mar 2008 08:39
- 1140 of 1451
"Gene therapy specialist Oxford Biomedica said it's full-year pretax loss narrowed to 17.7m versus 19.4m last time.
This left it with a cash position at the end of its financial year of 38.1m versus 28.5m last time.
The company said that it has completed the recruitment of a Phase III study in renal cancer for its lead drug TroVax, which is being developed along with Sanofi-Aventis.
The trial completion is seen as a key indicator of the potential of the drug. Brokerage KBC Peel Hunt pointed out before the results that, in conjunction with a successful Drug Safety Monitoring Board review, this could be seen as an indication of effectiveness, because the FDA board could have asked the company to increase the number of trial participants. "
If trovax is successful, this is a sure multi-bagger!! and thats without Prosavin, Lentivectors and the stream of other in research. But I don't think OXB will be able to remain independant for that long, they are bound to be taken over by someone like Sanofi or Glaxo.
robstuff
- 10 Mar 2008 09:06
- 1141 of 1451
The broadcast will be very positive - don't forget to tune in..
robstuff
- 10 Mar 2008 12:26
- 1142 of 1451
Panmure Gordon said in a note to clients: 'Oxford BioMedica reported financial results better than our expectations, and also provided an update on timelines for key product candidates that are also better than our, and market, expectations. We expect the stock to be positive and reiterate our Buy recommendation.'
The interesting thing about the financials too is that 19m of Sanofi's milestone paymts which have been paid and non refundable have been held over to next yrs profits so in fact the net profit position (as is cash flow) is actually positive isn't it.